Conclusion. Ceftobiprole is a novel, broad-spectrum, parenteral cephalosporin undergoing Phase III clinical trials. Its broad spectrum of activity makes it a candidate for monotherapy of cSSSIs ...

Patients were excluded if they had a history of an allergic reaction with or an intolerability to either cephalosporins or vancomycin, severe renal dysfunction (CL cr of <30 mL/min), hepatic ...